FDA Approved: ISTODAX — Supplemental Application (Celgene Corporation)

View source ↗

Summary

FDA approved a supplemental application for Istodax (romidepsin) to update its labeling, likely reflecting a new indication, safety, or other labeling changes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Istodax (romidepsin)

Snippet

SUPPL AP for ISTODAX (ROMIDEPSIN)